Gina M Webb, APRN-CNP Nurse Practitioner - Neonatal Medicare: Medicare Enrolled Practice Location: 4301 Greathouse Springs Rd, Johnson, AR 72741 Phone: 574-274-2322 |
Bridget Mary Mcclelland, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 4301 Greathouse Springs Road, Johnson, AR 72741 Phone: 901-270-9504 |
Mrs. Brandi Alexander, APRN Nurse Practitioner - Women's Health Medicare: Medicare Enrolled Practice Location: 4301 Greathouse Springs Road, Johnson, AR 72741 Phone: 479-684-3260 |
Jessica Jean Newcomb, APRN Nurse Practitioner - Pediatrics Medicare: Medicare Enrolled Practice Location: 4301 Greathouse Springs Road, Johnson, AR 72741 Phone: 479-684-3000 |
Marcie E Schock, Nurse Practitioner - Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 4301 Greathouse Springs Rd, Johnson, AR 72741 Phone: 479-674-3000 |
News Archive
One year after having a stroke, 52% of people who participate in either a physical therapy program that includes a walking program using a body-weight supported treadmill or a home-based program focused on progressive strength and balance exercises experience improved functional walking ability, according to the results of the Locomotor Experience Applied Post-stroke trial being presented today at the American Stroke Association's International Stroke Conference 2011 in Los Angeles.
The Arizona Republic reports: "One of the Mayo Clinic's two family-medicine practices in Arizona soon will stop accepting Medicare, leaving thousands of patients to pay out of pocket for routine doctor's visits or find a new physician." The changes go in effect on Jan. 1 and apply to primary-care services at the Mayo Clinic Family Medicine-Arrowhead.
Researchers from the University of North Carolina Lineberger Comprehensive Cancer Center estimate that screening for and treating prostate cancer in men aged 70 years or older, which is not recommended by national guidelines, cost Medicare more than $1.2 billion over a three year period for each group of men diagnosed in the United States each year.
OncoGenex Pharmaceuticals Inc. today announced that it concluded a meeting with the U.S. Food and Drug Administration (FDA) on October 7, 2008, and that the FDA agreed that "durable pain palliation is an acceptable and desirable study endpoint" to support a product marketing approval for OGX-011 as a treatment for hormone refractory prostate cancer (HRPC).
Virginia Tech researcher Pavlos Vlachos and his students in the College of Engineering have a tall order to tackle: Stem the grim progression of heart disease, which kills hundreds of thousands of people each year in the United States alone.
› Verified 7 days ago